colorectal cancer cell lines ht 29  (ATCC)

Journal: Natural Products and Bioprospecting

Article Title: Combined treatment with naringin and osthole ameliorates colitis through microbiota–amino acid metabolism and the JNK pathway

doi: 10.1007/s13659-025-00582-z

Figure Lengend Snippet: Combination therapy of naringin and osthole inhibits inflammatory damage in vitro. A – C CCK-8 detection of cell viability. D Perform RT-qPCR on IL-6, IL-1β, TNF-α, and IL-10 in HT-29 cells. E – G Western blotting and quantitative analysis of apoptosis factors Bcl-2, Bax, and Cleaved-Caspase-3. Data are presented as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Article Snippet: The human colon cancer cell line HT-29 was obtained from the American Type Culture Collection (ATCC, USA) and were cultured in DMEM containing 100 IU/mL penicillin, 100 μg/mL streptomycin, and 10% fetal bovine serum (FBS) in a humidified incubator at 37 °C with 5% CO 2 .

Techniques: In Vitro, CCK-8 Assay, Quantitative RT-PCR, Western Blot

Journal: Natural Products and Bioprospecting

Article Title: Combined treatment with naringin and osthole ameliorates colitis through microbiota–amino acid metabolism and the JNK pathway

doi: 10.1007/s13659-025-00582-z

Figure Lengend Snippet: The combined administration of naringin and osthole alleviates colitis in mice by inhibiting the JNK/NF-κB signaling pathway in vitro and in vivo. A , B Western blot for NF-κB signing pathway in vivo and in vitro. C , D Western blot for JNK signing pathway in vivo and in vitro. E Western blot of JNK signing pathway in vitro after JNK inhibitor (SP600125) treatment. Data are presented as mean ± SEM (n = 3). F RT-qPCR of IL-6, IL-1β, TNF-α and IL-10 in HT-29 cells after pretreatment with JNK inhibitor SP600125. Data are presented as mean ± SEM (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001

Article Snippet: The human colon cancer cell line HT-29 was obtained from the American Type Culture Collection (ATCC, USA) and were cultured in DMEM containing 100 IU/mL penicillin, 100 μg/mL streptomycin, and 10% fetal bovine serum (FBS) in a humidified incubator at 37 °C with 5% CO 2 .

Techniques: In Vitro, In Vivo, Western Blot, Quantitative RT-PCR

Journal: bioRxiv

Article Title: Molidustat Targets a Synthetic Lethal Vulnerability in APC-Mutant Colorectal Cancer through GSTP1 and PHD2 Co-Inhibition

doi: 10.64898/2026.01.31.702998

Figure Lengend Snippet: A. Percentage of Cleaved Caspase 3/7 positive HT29 (top), and RKO (bottom) cells. Cells were treated with Molidustat for 48 hours at indicated concentrations, 10uM Staurosporine was used as a positive control (100% cell death). Mean + SEM is assessed by unpaired two tailed Student’s t-test, **p<0.01, (ns) non-significant. B. Representative images of Cleaved Caspase-3/7 signal in DMSO, Molidustat (90 μM), and Staurosporine treated cells. Scale bar: 300 μm. C. Representative Western Blot of PHD2 levels in HT29 cells. D. Percentage confluency of HT29 cells post-transfection with the indicated guide RNAs. E. Cleaved Caspase-3/7 signal in HT29 cells post-transfection with the indicated crRNAs. Mean + SEM is assessed by two-way ANOVA, *p<0.05. N = 3 biologically independent experiments.

Article Snippet: Human colorectal cancer cell lines HT29 and RKO were obtained from the American Type Culture Collection (ATCC) and maintained in Dulbecco’s Modified Eagle Medium (DMEM; Sigma-Aldrich, D6429) supplemented with 10% (v/v) fetal bovine serum (FBS; Gibco, 16000044), 1% (v/v) penicillin-streptomycin (Gibco, 15140122), and 2 mM L-glutamine (Sigma-Aldrich, G7513).

Techniques: Positive Control, Two Tailed Test, Western Blot, Transfection

Journal: bioRxiv

Article Title: Spatiotemporal Atlas of Pro-Inflammatory (NF-κB) and Anti-Inflammatory (STAT6) Signalling Using Reporter Mice during mRNA Vaccination

doi: 10.64898/2026.01.29.702227

Figure Lengend Snippet: (A) Luciferase activity was measured in RAW 264.7 cells transiently co-transfected with the p2xSTAT6 -GFP- luc2 construct and treated with 20 ng/ml cytokines for 24 h, 2 µg/ml LPS for 6 h, or vehicle (water). Data are mean ± SD (n = 4) of luciferase activity (RLU) normalized to total protein content. ***p < 0.001, **p < 0.01 versus vehicle (one-way ANOVA, Dunnett’s test). (B) Representative fluorescence microscopy images showing GFP expression in HT-29 cells transfected with the p2xSTAT6-GFP-luc2 construct and a constitutively expressing tdTomato plasmid and treated with 20 ng/ml IL-4, 100 ng/ml LPS, or vehicle (water) for 24 h. Scale bar: 50 µm. (C) Schematic representation of the STAT6-STOP and STAT6- luc2 reporter mouse models. The transgene, shown before and after excision of the STOP sequence, was inserted into chromosome 7 (Chr7) of reporter mice by homologous recombination, The mouse line carrying the STOP cassette is referred to as STAT6-STOP. Breeding with B6.C-Tg(CMV-cre)1Cgn/J mice (Cre) leads to Cre-mediated excision of the STOP sequence, generating the STAT6- luc2 line. Abbreviations: 5HR, 3HR:homologous regions for chromosomal integration; MAR: Matrix Attachment Regions; 2XSTAT6: STAT6 promoter; STOP: POLR2 (RNA polymerase II) termination signal; loxP: locus of X-over P1; GFP: green fluorescent protein; luc2 : optimized firefly luciferase 2; IRES: internal ribosome entry site; Frt: Flp recombination target sites. On the right, representative pseudocolor images of ventral luciferase emission from STAT6-STOP and STAT6-luc2 female mice are shown according to the indicated scale bar.

Article Snippet: RAW 264.7 and HT-29 cell lines were obtained from the American Type Culture Collection (ATCC) and cultured in cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, Cat.11965-092) supplemented with 10% fetal bovine serum (FBS; Gibco, Cat. A5209502), 1 mM Sodium Pyruvate (Gibco, Cat.11360070) and 1% Antibiotic-Antimycotic (Gibco, Cat. 15240-062), and maintained at 37 °C in a humidified atmosphere containing 5% CO 2 .

Techniques: Luciferase, Activity Assay, Transfection, Construct, Fluorescence, Microscopy, Expressing, Plasmid Preparation, Sequencing, Homologous Recombination